This fortnight's standout story is a sweeping FDA CDRH housekeeping exercise that withdrew recognition from more than 30 consensus standards in a single day (6 July 2026), spanning implant materials, biocompatibility, respiratory/anaesthetic equipment, cardiovascular devices, MRI, and health informatics. For any manufacturer whose technical file or 510(k) cites these standards for the presumption-of-conformity pathway, immediate action is required. We have grouped the withdrawals into a single headline item and called out the highest-impact individual derecognitions separately. Elsewhere, MHRA has demonstrated it will pursue criminal enforcement for device-marking fraud, and FDA has opened the MDUFA V stakeholder process — a planning horizon item for every company that pays US device user fees.
FDA Withdraws Recognition of 30+ Consensus Standards in Single-Day Purge — Immediate Technical-File Review Required
FDA · US
On 6 July 2026, FDA CDRH removed recognition from a large cohort of ASTM, ISO, IEC, IEEE, ANSI/ADA, CGA, and NEMA standards across virtually every device category. Declarations of Conformity citing any of these standards no longer satisfy FDA's presumption-of-conformity pathway. Affected areas include: orthopaedic implant alloys (ASTM F1472, F1295); surgical-instrument stainless steel (ASTM F899); MR-environment safety marking (ASTM F2503); intravascular catheters (ISO 10555-1, -4); breathing-gas biocompatibility (ISO 18562 series); cardiovascular centrifugal pumps (ISO 18242); interventional X-ray equipment (IEC 60601-2-43); medical beds (IEC 60601-2-52); resorbable biomaterials (ASTM F1983); UHMWPE aging (ASTM F2003); Ni-Ti superelastic materials (ASTM F2516); animal welfare in biocompatibility (ISO 10993-2); neurofeedback systems (IEEE 2010); dental water-based cements (ANSI ADA 96); point-of-care/personal health device communication (ISO/IEEE 11073 series); and medical gas cylinder connections (CGA standards). Regulatory affairs teams must audit all current and in-preparation submissions to identify reliance on any withdrawn standard and substitute with the current recognised version or provide alternative conformity evidence.
Read the source →HIGH PRIORITY — FDA Withdraws ASTM F2503-20 Recognition: MR-Environment Safety Marking Standard Derecognised
FDA · US
ASTM F2503 is the foundational standard for MR Conditional/MR Safe/MR Unsafe marking on implants and devices used in MRI environments. Its derecognition is particularly high-impact because it underpins labelling claims across thousands of device types. Manufacturers who have cited this standard in 510(k) submissions or PMA supplements must identify and cite the current recognised replacement. Failure to do so could result in deficiency letters or requests for additional information on pending submissions, and may affect post-market labelling compliance.
Read the source →FDA Withdraws ISO 18562 Series (Parts 1–4): Breathing-Gas-Pathway Biocompatibility Standards All Derecognised
FDA · US
All four parts of the ISO 18562 series — covering risk-management framework, particulate emissions, VOC emissions, and leachables in condensate for breathing gas pathways — have been simultaneously derecognised. This affects manufacturers of ventilators, anaesthetic machines, CPAP/BiPAP devices, respiratory circuits, and any device with a gas-contact pathway. Biocompatibility sections of technical files and premarket submissions citing these parts must be reviewed. Manufacturers should check whether updated editions have since been published and whether FDA has recognised those newer versions.
Read the source →MDUFA V Reauthorisation Public Meeting Announced — Industry Input Sought for FY2028–2032 Fee Framework
FDA · US
FDA has announced a hybrid public meeting to discuss recommendations for reauthorising the Medical Device User Fee Amendments covering fiscal years 2028–2032. The current MDUFA authority expires 30 September 2027. This is a material planning issue for all companies paying 510(k), De Novo, PMA, or establishment registration fees: the reauthorisation process will set performance goals, review timelines, and fee levels that govern FDA's device review capacity for the next five-year cycle. Small manufacturers and consultancies should engage now — historically, MDUFA negotiations shape FDA staffing and review speed. Monitor the Federal Register for comment deadlines and meeting registration details.
Read the source →MHRA Secures Criminal Convictions for Fraudulently Marked Baby-Feeding Devices — Enforcement Signal for All CE/UKCA Manufacturers
MHRA · UK
Following a decade-long investigation, MHRA has secured fraud convictions related to the supply of non-compliant medical devices bearing false markings. Although the case involved baby-feeding devices, it sends a strong enforcement signal across the entire medical device sector: MHRA is willing and able to pursue criminal prosecution — not just civil regulatory action — for device-marking non-compliance. For RA teams, this underlines the importance of robust supply-chain due diligence, Declaration of Conformity integrity, and accurate UKCA/CE marking. Distributors and importers placing devices on the UK market carry specific legal obligations and face equivalent liability.
Read the source →MHRA CEO Sets Out Vision for Regulation as an Innovation Catalyst — Strategic Positioning for UK Market Access
MHRA · UK
The MHRA Chief Executive has published a strategic statement arguing that UK regulation should lead, not follow, innovation in life sciences. This signals continued MHRA intent to use tools such as the Innovation Accelerator and Innovation Office to reduce regulatory friction for novel devices. For small and mid-sized manufacturers, this is a practical prompt to engage proactively with MHRA's pre-submission advice routes — particularly relevant for AI/ML-enabled devices, combination products, and first-in-class technologies seeking UK market access ahead of or alongside EU MDR conformity assessment.
Read the source →MHRA Field Safety Notices: 29 June – 3 July 2026 — Weekly Round-Up
MHRA · UK
MHRA has published the weekly Field Safety Notice (FSN) digest covering 29 June to 3 July 2026. Manufacturers, importers, and distributors with devices on the UK market should review the full list to identify any products in their portfolio or supply chain. FSNs may trigger obligations under UK MDR 2002 (as amended) for Economic Operators, including customer notification, field corrective action, and MHRA reporting. RA teams should also cross-reference against the prior week's FSN digest (22–26 June) published simultaneously.
Read the source →FDA PMA Information Collection Resubmitted to OMB — Administrative but Operationally Relevant
FDA · US
FDA has submitted the Premarket Approval (PMA) information collection package to the Office of Management and Budget for renewal under the Paperwork Reduction Act. While procedural, any lapse or amendment to OMB clearance can affect FDA's ability to process PMA submissions, supplements, and annual reports. Companies with active or planned PMA filings — particularly those preparing Class III submissions or PMA supplements for significant device modifications — should monitor the outcome. The notice also provides an opportunity to submit public comments on the administrative burden of PMA requirements.
Read the source →